Investigation of the Cerebral Energy Status in Patients with Glutaric Aciduria Type I by ³¹P Magnetic Resonance Spectroscopy

 

 Buy Article Permissions and Reprints

Abstract

In vivo phosphorus magnetic resonance spectroscopy (MRS) was used to investigate markers of the cerebral energy status in two patients with glutaric aciduria type I (GA-I). Besides an increased concentration of phosphomonoesters in one patient, no other significant alterations from controls were found. This might indicate increased resynthesis of dendritic processes secondary to preceding metabolic crises. In contrast to previous cell-culture studies, no cerebral depletion of phosphocreatine (PCr) was observed. In conclusion, a severe global and permanent depletion of cerebral energy supplies must be ruled out. The benefit of a permanent creatine substitution to stabilize mitochondrial energy metabolism seems thus questionable. However, as MRS was performed during stable clinical conditions, the possibility of a PCr decrease during acute metabolic crises cannot be assessed.

References

• 1 Amir N, el-Peleg O, Shalev R S, Christensen E. Glutaric aciduria type I: Clinical heterogeneity and neuroradiologic features.  Neurology. 1987;  37 1654-1657
  PubMedGoogle Scholar
• 2 Bjugstad K B, Goodman S I, Freed C R. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1.  J Pediatr. 2000;  137 681-686
  CrossrefPubMedGoogle Scholar
• 3 Brismar J, Ozand P T. CT and MR of the brain in glutaric acidemia type I: A review of 59 published cases and a report of 5 new patients.  AJNR Am J Neuroradiol. 1995;  16 675-683
  PubMedGoogle Scholar
• 4 Brown T R, Kincaid B M, Ugurbil K. NMR chemical shift imaging in three dimensions.  Proc Natl Acad Sci USA. 1982;  79 3523-3526
  CrossrefPubMedGoogle Scholar
• 5 Buchli R, Duc C I, Martin E, Boesiger P. Assessment of absolute metabolite concentrations in human tissue by ³¹P MRS in vivo. Part I: Cerebrum, cerebellum, cerebral gray and white matter.  Magn Reson Med. 1994;  32 447-452
  PubMedGoogle Scholar
• 6 Das A M, Lücke T, Ullrich K. Glutaric aciduria I. Creatine supplementation restores creatine phosphate in mixed cortex cells incubated with 3-hydroxyglutarate.  J Inher Metab Dis. 2000;  23 (Suppl 1) 100
  PubMedGoogle Scholar
• 7 Flott-Rahmel B, Falter C, Schluff P, Fingerhut R, Christensen E, Jakobs C. et al . Nerve cell lesions caused by 3-hydroxyglutaric acid: A possible mechanism for neurodegeneration in glutaric acidemia I.  J Inher Metab Dis. 1997;  20 387-390
  PubMedGoogle Scholar
• 8 Goodman S I, Norenberg M D, Shikes R H, Breslich D J, Moe P G. Glutaric aciduria: Biochemical and morphologic considerations.  J Pediatr. 1977;  90 746-750
  CrossrefPubMedGoogle Scholar
• 9 Gregersen N, Brandt N J. Ketotic episodes in glutaryl-CoA dehydrogenase deficiency (glutaric aciduria).  Pediatr Res. 1979;  13 977-981
  PubMedGoogle Scholar
• 10 Hoffmann G F, Gibson K M, Trefz F K, Nyhan W L, Bremer H J, Rating D. Neurological manifestations of organic-acid disorders.  Eur J Pediatr. 1994;  153 (Suppl 1) S94-S100
  PubMedGoogle Scholar
• 11 Hoffmann G F, Athanassopoulos S, Burlina A B, Duran M, de Klerk J BC, Lehnert W. et al . Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency.  Neuropediatrics. 1996;  27 115-123
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Kölker S, Ahlemeyer B, Kriegelstein J, Hoffmann G F. 3-Hydroxyglutaric and glutaric acids are neurotoxic through NMDA receptors in vitro.  J Inher Metab Dis. 1999;  22 259-262
  PubMedGoogle Scholar
• 13 Kölker S, Bachmann C, Hoffmann G F. Creatine attenuates excitotoxicity in an in vitro model of glutaric aciduria type 1: Impact for therapy?.  J Inher Metab Dis. 2000;  23 (Suppl 1) 101
  PubMedGoogle Scholar
• 14 Land J M, Goulder P, Johnson A, Hockaday J. Glutaric aciduria type-1 - an atypical presentation together with some observations upon treatment and the possible cause of cerebral damage.  Neuropediatrics. 1992;  23 322-326
  PubMedGoogle Scholar
• 15 Leibel R L, Shih V E, Goodman S I, Bauman M L, McCabe E R, Zwerdling R G. et al . Glutaric acidemia: A metabolic disorder causing progressive choreoatheosis.  Neurology. 1980;  30 1163-1168
  PubMedGoogle Scholar
• 16 Möller H E, Ullrich K, Vermathen P, Schuierer G, Koch H G. In vivo study of brain metabolism in galactosemia by ¹H and ³¹P magnetic resonance spectroscopy.  Eur J Pediatr. 1995;  154 (Suppl 2) S8-S13
  PubMedGoogle Scholar
• 17 Möller H E, Vermathen P, Rummeny E, Wörtler K, Wuisman P, Rössner A. et al . In vivo ³¹P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy.  NMR Biomed. 1996;  9 347-358
  CrossrefPubMedGoogle Scholar
• 18 Pettegrew J W, Kopp S J, Minshew N J, Glonek T, Feliksik J M, Tow J P. et al . ³¹P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: Preliminary observations.  J Neuropathol Exp Neurol. 1987;  46 419-430
  PubMedGoogle Scholar
• 19 Taylor D J, Styles P, Matthews P M, Arnold D A, Gadian D G, Bore P. et al . Energetics of human muscle: Exercise-induced ATP depletion.  Magn Reson Med. 1986;  3 44-54
  PubMedGoogle Scholar
• 20 Ullrich K, Flott-Rahmel B, Schluff P, Musshoff U, Das A, Lücke T. Glutaric aciduria type I: Pathomechanisms of neurodegeneration.  J Inher Metab Dis. 1999;  22 392-403
  CrossrefPubMedGoogle Scholar

Ph.D. Harald E. Möller

Max Planck Institute of Cognitive Neuroscience

Stephanstraße 1 a

04103 Leipzig

Germany

Email: moeller@cns.mpg.de